🔎 Trials Near Me

መነሻ › በርኪት ሊምፎማ › አይዳሆ › Boise

በBoise፣ ID ለበርኪት ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች

ለበርኪት ሊምፎማ የሚደረጉ 5 ጥናቶች በBoise እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Saint Luke's Cancer Institute - Boise, Boise
366 Days – 46 Years · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Saint Alphonsus Cancer Care Center-Boise, Boise
እድሜ ከ18 እስከ 39 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Saint Luke's Cancer Institute - Boise, Boise
365 Days · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Saint Luke's Cancer Institute - Boise, Boise
እድሜ ከ1 እስከ 30 · ሁሉም ጾታዎች · የተሻሻለው በ1 ሴፕቴ 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Saint Luke's Cancer Institute - Boise, Boise
365 Days – 25 Years · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT03959085

በሌሎች ከተሞች ለበርኪት ሊምፎማ የሚደረጉ ጥናቶች

በBoise ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።